Description: Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Home Page: aadibio.com
17383 Sunset Boulevard
Pacific Palisades,
CA
90272
United States
Phone:
424 744 8055
Officers
| Name | Title |
|---|---|
| Mr. David J. Lennon Ph.D. | President, CEO & Director |
| Mr. Scott M. Giacobello CPA | CFO, Treasurer, Investor Relations & Corporate Communications |
| Mr. Stephen M. Rodin J.D. | Senior VP of Legal & General Counsel |
| Mr. Raymond G. Steitz | Senior VP of Human Resources & Chief Human Resources Officer |
| Mr. Bryan Ball | Chief Technical Operations Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8107 |
| Price-to-Sales TTM: | 2.2072 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 53 |